SAN FRANCISCO — Girard Gibbs LLP (http://www.girardgibbs.com) is investigating an alleged securities fraud by Schering-Plough Corp., Inc. (”Schering-Plough”) and certain of its executives between July 24, 2006 and January 14, 2008.
It is alleged that Schering-Plough issued a series of material misrepresentatio…
More than 50 cases pending, including Missouri’s Western, Eastern districts
Recent controversy surrounding the cholesterol pill Vytorin has attorneys across the country filing lawsuits and scrambling for class action status.
Since a study was released about two weeks ago questioning Vytorin’s ability to reduce plaque buildup in the arteries, more than 50 lawsuits have been filed in U.S. federal courts against the drug’s man…
Byline: RICH THOMASELLI and IRA TEINOWITZ
First came headlines that a study showing that cholesterol drug Vytorin doesn’t reduce plaque buildup in arteries was delayed by drug makers that spent millions advertising the claim. Then came news that Eli Lilly & Co. might pay an astounding $1 billion to settle a federal investigation into the marketing of its antipsychotic drug Zyprexa, potentially the largest sum ever paid by a drug company for breaking feder…
Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia)
FDA Investigates a Report from the SEAS Trial
This information reflects FDA’s current analysis of available data concerning these drugs. Posting this…
Jan. 25, 2008 — The FDA says it will explore the medical mystery of why Vytorin cuts cholesterol but doesn’t seem to reduce plaque in the arteries.
Vytorin is a combination of two different types of cholesterol-lowering drugs: Zetia, which blocks cholesterol absorption in the gut, and Zocor, one of the statin drugs that slows cholesterol production. Other statins include Crestor…
IN WASHINGTON, the saying goes, it’s not the crime but the cover-up that gets you.
Merck/Schering-Plough’s Vytorin debacle isn’t Watergate. It’s not even on par with some of the recent safety scandals still sendi…
MUNICH, Germany — Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged Tuesday.
The New England Journal of Medicine published results online from one study and an analysis of partial results from two oth…
A controversial study showing that the blockbuster cholesterol-lowering drug Vytorin failed to slow the buildup of artery plaques more than a cheaper statin is certain to provoke questions among heart patients taking Vytorin or its sister drug Zetia. USA TODAY medical reporter Steve Sternberg asked Steven Nissen, the Cleveland Clinic’s chief of cardiology, and Roger Blumenthal of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and the Americ…
